Innovation

An expert in TAR DNA-binding protein of 43 kDa (TDP-43), neuropathologist Qinwen Mao, MD, PhD, subspecialty director of Neuropathology at ARUP, is working to identify biomarkers that predict the presence of TDP-43 pathology to contribute to the diagnosis of frontotemporal lobar degeneration (FTLD) and Alzheimer’s disease.

ARUP survey shows “profound” concern within the lab community about the FDA’s proposed rule.

Tracy George, MD (third from right), ARUP’s chief scientific officer and president of the Innovation Business Unit, holds a zebra, the mascot for patients with rare diseases, and poses for a photo with participants in Salt Lake City’s Rare Disease Day event. Pictured, from left to right, are Tanner Withers, parent of a child with a rare disease, Troy Evans, undiagnosed patient with a rare disease, Rebecca Yates, parent of a child with a rare disease, Matt Pearl, patient with a rare disease, Ava and Lucy Szajunk, undiagnosed patients with rare diseases, George, Chris Gibson, PhD, CEO of Recursion, and Kelvyn Cullimore, president and CEO of BioUtah.

MetaCensus is built to support the exchange and review of data by various stakeholders and performs multicriteria decision analysis (MCDA) to assess and account for varying perspectives, counterpoints, and biases.

ARUP medical directors and scientists, including (from left to right) Sherin Shaaban, MD, PhD, FACMG; Yuan Ji, PhD, MBA, DABCP, FACMG; and Hunter Best, PhD, FACMG, along with others, will present their latest research and share insights for current and future geneticists at the Annual Clinical Genetics Meeting in March.

ARUP medical directors and scientists advanced laboratory medicine and improved patient care with publication of more than 130 peer-reviewed articles in fiscal year 2023.

Melanie Mallory, MS, lead bioinformatics scientist at ARUP Laboratories, played a key role in the development and validation of ARUP’s Cytomegalovirus Drug Resistance by Next Generation Sequencing assay.

Madhu Menon, MD, PhD, FCAP, ARUP’s section chief of Hematopathology, works with a team of experts to deliver accurate and timely results.

The AAV5 DetectCDx™ Kit received its Conformitée Européene (CE) mark in January 2022, and testing is being performed by a Medicover facility in Germany.

AAV5 DetectCDx™ detects the presence of anti-AAV5 antibodies to aid in the selection of patients eligible for the treatment ROCTAVIAN™.

From left, Greg Critchfield, Myriad Genetics and Sera Prognostics; Mark Poritz, Co-Diagnostics; Kyle Berg, Quansys Biosciences; Jared Bauer, Seek Labs; Tracy I. George, ARUP Laboratories; and Andrew Hemmert, bioMerieux. These panelists addressed challenges facing diagnostics companies during a discussion at the Utah Life Sciences Summit in Salt Lake City on November 9.